nodes	percent_of_prediction	percent_of_DWPC	metapath
L-DOPA—PSIP1—prostate gland—urinary bladder cancer	0.0209	0.0765	CbGeAlD
L-DOPA—PSIP1—seminal vesicle—urinary bladder cancer	0.0177	0.0647	CbGeAlD
L-DOPA—PSIP1—renal system—urinary bladder cancer	0.0143	0.0521	CbGeAlD
L-DOPA—PSIP1—urethra—urinary bladder cancer	0.014	0.0512	CbGeAlD
L-DOPA—SLC7A8—prostate gland—urinary bladder cancer	0.0138	0.0504	CbGeAlD
L-DOPA—PSIP1—female reproductive system—urinary bladder cancer	0.0114	0.0418	CbGeAlD
L-DOPA—SLC7A5—prostate gland—urinary bladder cancer	0.0107	0.0391	CbGeAlD
L-DOPA—PSIP1—vagina—urinary bladder cancer	0.0103	0.0378	CbGeAlD
L-DOPA—PSIP1—Podofilox—Etoposide—urinary bladder cancer	0.00964	0.5	CbGdCrCtD
L-DOPA—PSIP1—Teniposide—Etoposide—urinary bladder cancer	0.00964	0.5	CbGdCrCtD
L-DOPA—SLC7A8—renal system—urinary bladder cancer	0.00939	0.0344	CbGeAlD
L-DOPA—SLC7A5—seminal vesicle—urinary bladder cancer	0.00904	0.033	CbGeAlD
L-DOPA—CYP2D6—urine—urinary bladder cancer	0.00867	0.0317	CbGeAlD
L-DOPA—SLC16A10—prostate gland—urinary bladder cancer	0.00818	0.0299	CbGeAlD
L-DOPA—DDC—renal system—urinary bladder cancer	0.00813	0.0297	CbGeAlD
L-DOPA—SLC7A5—epithelium—urinary bladder cancer	0.00785	0.0287	CbGeAlD
L-DOPA—SLC7A5—smooth muscle tissue—urinary bladder cancer	0.00756	0.0277	CbGeAlD
L-DOPA—SLC7A8—female reproductive system—urinary bladder cancer	0.00752	0.0275	CbGeAlD
L-DOPA—SLC7A5—urethra—urinary bladder cancer	0.00715	0.0262	CbGeAlD
L-DOPA—SLC7A8—vagina—urinary bladder cancer	0.0068	0.0249	CbGeAlD
L-DOPA—PSIP1—lymph node—urinary bladder cancer	0.00668	0.0244	CbGeAlD
L-DOPA—SLC15A1—epithelium—urinary bladder cancer	0.00652	0.0238	CbGeAlD
L-DOPA—DDC—female reproductive system—urinary bladder cancer	0.00651	0.0238	CbGeAlD
L-DOPA—DRD5—female reproductive system—urinary bladder cancer	0.00626	0.0229	CbGeAlD
L-DOPA—SLC15A1—renal system—urinary bladder cancer	0.00604	0.0221	CbGeAlD
L-DOPA—SLC16A10—epithelium—urinary bladder cancer	0.00601	0.022	CbGeAlD
L-DOPA—SLC7A5—female reproductive system—urinary bladder cancer	0.00583	0.0213	CbGeAlD
L-DOPA—SLC7A5—vagina—urinary bladder cancer	0.00527	0.0193	CbGeAlD
L-DOPA—SLC16A10—female reproductive system—urinary bladder cancer	0.00447	0.0163	CbGeAlD
L-DOPA—SLC7A8—lymph node—urinary bladder cancer	0.0044	0.0161	CbGeAlD
L-DOPA—SLC15A1—vagina—urinary bladder cancer	0.00438	0.016	CbGeAlD
L-DOPA—Aminosalicylic Acid—MPO—urinary bladder cancer	0.00406	0.285	CrCbGaD
L-DOPA—SLC16A10—vagina—urinary bladder cancer	0.00404	0.0148	CbGeAlD
L-DOPA—DDC—lymph node—urinary bladder cancer	0.00381	0.0139	CbGeAlD
L-DOPA—SLC7A5—lymph node—urinary bladder cancer	0.00341	0.0125	CbGeAlD
L-DOPA—Mesalazine—MPO—urinary bladder cancer	0.00318	0.224	CrCbGaD
L-DOPA—Mesalazine—PPARG—urinary bladder cancer	0.00283	0.199	CrCbGaD
L-DOPA—SLC16A10—lymph node—urinary bladder cancer	0.00261	0.00955	CbGeAlD
L-DOPA—CYP2D6—renal system—urinary bladder cancer	0.00212	0.00776	CbGeAlD
L-DOPA—CYP2D6—female reproductive system—urinary bladder cancer	0.0017	0.00621	CbGeAlD
L-DOPA—Aminosalicylic Acid—PTGS2—urinary bladder cancer	0.00152	0.107	CrCbGaD
L-DOPA—Epinephrine—TNF—urinary bladder cancer	0.00145	0.102	CrCbGaD
L-DOPA—Mesalazine—PTGS2—urinary bladder cancer	0.00119	0.0839	CrCbGaD
L-DOPA—Decreased appetite—Cisplatin—urinary bladder cancer	0.000648	0.00121	CcSEcCtD
L-DOPA—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000647	0.00121	CcSEcCtD
L-DOPA—Nasopharyngitis—Doxorubicin—urinary bladder cancer	0.000644	0.0012	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000643	0.0012	CcSEcCtD
L-DOPA—Depression—Methotrexate—urinary bladder cancer	0.000639	0.00119	CcSEcCtD
L-DOPA—Hypotension—Etoposide—urinary bladder cancer	0.000638	0.00119	CcSEcCtD
L-DOPA—Gastritis—Doxorubicin—urinary bladder cancer	0.000637	0.00119	CcSEcCtD
L-DOPA—Pain—Cisplatin—urinary bladder cancer	0.000637	0.00119	CcSEcCtD
L-DOPA—Dizziness—Thiotepa—urinary bladder cancer	0.000628	0.00117	CcSEcCtD
L-DOPA—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.000625	0.00117	CcSEcCtD
L-DOPA—Urticaria—Fluorouracil—urinary bladder cancer	0.000624	0.00116	CcSEcCtD
L-DOPA—Dysphagia—Doxorubicin—urinary bladder cancer	0.000622	0.00116	CcSEcCtD
L-DOPA—Pollakiuria—Epirubicin—urinary bladder cancer	0.000621	0.00116	CcSEcCtD
L-DOPA—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000614	0.00115	CcSEcCtD
L-DOPA—Paraesthesia—Etoposide—urinary bladder cancer	0.000613	0.00114	CcSEcCtD
L-DOPA—Weight increased—Epirubicin—urinary bladder cancer	0.000612	0.00114	CcSEcCtD
L-DOPA—Weight decreased—Epirubicin—urinary bladder cancer	0.000609	0.00114	CcSEcCtD
L-DOPA—Dyspnoea—Etoposide—urinary bladder cancer	0.000608	0.00114	CcSEcCtD
L-DOPA—Somnolence—Etoposide—urinary bladder cancer	0.000607	0.00113	CcSEcCtD
L-DOPA—Angina pectoris—Doxorubicin—urinary bladder cancer	0.000606	0.00113	CcSEcCtD
L-DOPA—Vomiting—Thiotepa—urinary bladder cancer	0.000604	0.00113	CcSEcCtD
L-DOPA—Rash—Thiotepa—urinary bladder cancer	0.000599	0.00112	CcSEcCtD
L-DOPA—Dermatitis—Thiotepa—urinary bladder cancer	0.000598	0.00112	CcSEcCtD
L-DOPA—Agranulocytosis—Methotrexate—urinary bladder cancer	0.000598	0.00112	CcSEcCtD
L-DOPA—Headache—Thiotepa—urinary bladder cancer	0.000595	0.00111	CcSEcCtD
L-DOPA—Decreased appetite—Etoposide—urinary bladder cancer	0.000593	0.00111	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000589	0.0011	CcSEcCtD
L-DOPA—Fatigue—Etoposide—urinary bladder cancer	0.000588	0.0011	CcSEcCtD
L-DOPA—Neuropathy peripheral—Epirubicin—urinary bladder cancer	0.000588	0.0011	CcSEcCtD
L-DOPA—Pain—Etoposide—urinary bladder cancer	0.000584	0.00109	CcSEcCtD
L-DOPA—Constipation—Etoposide—urinary bladder cancer	0.000584	0.00109	CcSEcCtD
L-DOPA—Urinary tract infection—Epirubicin—urinary bladder cancer	0.000583	0.00109	CcSEcCtD
L-DOPA—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000579	0.00108	CcSEcCtD
L-DOPA—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000578	0.00108	CcSEcCtD
L-DOPA—Haemoglobin—Methotrexate—urinary bladder cancer	0.000578	0.00108	CcSEcCtD
L-DOPA—Haemorrhage—Methotrexate—urinary bladder cancer	0.000575	0.00107	CcSEcCtD
L-DOPA—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000575	0.00107	CcSEcCtD
L-DOPA—Asthenia—Gemcitabine—urinary bladder cancer	0.000573	0.00107	CcSEcCtD
L-DOPA—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000568	0.00106	CcSEcCtD
L-DOPA—Weight increased—Doxorubicin—urinary bladder cancer	0.000566	0.00106	CcSEcCtD
L-DOPA—Pruritus—Gemcitabine—urinary bladder cancer	0.000565	0.00105	CcSEcCtD
L-DOPA—Nausea—Thiotepa—urinary bladder cancer	0.000564	0.00105	CcSEcCtD
L-DOPA—Urethral disorder—Methotrexate—urinary bladder cancer	0.000564	0.00105	CcSEcCtD
L-DOPA—Weight decreased—Doxorubicin—urinary bladder cancer	0.000563	0.00105	CcSEcCtD
L-DOPA—Feeling abnormal—Etoposide—urinary bladder cancer	0.000562	0.00105	CcSEcCtD
L-DOPA—Agranulocytosis—Epirubicin—urinary bladder cancer	0.00056	0.00104	CcSEcCtD
L-DOPA—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000558	0.00104	CcSEcCtD
L-DOPA—Pruritus—Fluorouracil—urinary bladder cancer	0.000556	0.00104	CcSEcCtD
L-DOPA—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000549	0.00102	CcSEcCtD
L-DOPA—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000547	0.00102	CcSEcCtD
L-DOPA—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000544	0.00101	CcSEcCtD
L-DOPA—Urticaria—Etoposide—urinary bladder cancer	0.000542	0.00101	CcSEcCtD
L-DOPA—Haemoglobin—Epirubicin—urinary bladder cancer	0.000541	0.00101	CcSEcCtD
L-DOPA—Rhinitis—Epirubicin—urinary bladder cancer	0.00054	0.00101	CcSEcCtD
L-DOPA—Abdominal pain—Etoposide—urinary bladder cancer	0.000539	0.00101	CcSEcCtD
L-DOPA—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000539	0.00101	CcSEcCtD
L-DOPA—Haemorrhage—Epirubicin—urinary bladder cancer	0.000538	0.001	CcSEcCtD
L-DOPA—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000538	0.001	CcSEcCtD
L-DOPA—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000536	0.001	CcSEcCtD
L-DOPA—Asthenia—Cisplatin—urinary bladder cancer	0.000534	0.000997	CcSEcCtD
L-DOPA—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000532	0.000992	CcSEcCtD
L-DOPA—Urethral disorder—Epirubicin—urinary bladder cancer	0.000528	0.000985	CcSEcCtD
L-DOPA—Dizziness—Fluorouracil—urinary bladder cancer	0.00052	0.000969	CcSEcCtD
L-DOPA—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000518	0.000966	CcSEcCtD
L-DOPA—Diarrhoea—Cisplatin—urinary bladder cancer	0.00051	0.000951	CcSEcCtD
L-DOPA—Alopecia—Methotrexate—urinary bladder cancer	0.000508	0.000949	CcSEcCtD
L-DOPA—Vomiting—Gemcitabine—urinary bladder cancer	0.000508	0.000948	CcSEcCtD
L-DOPA—Mental disorder—Methotrexate—urinary bladder cancer	0.000504	0.00094	CcSEcCtD
L-DOPA—Rash—Gemcitabine—urinary bladder cancer	0.000504	0.00094	CcSEcCtD
L-DOPA—Dermatitis—Gemcitabine—urinary bladder cancer	0.000503	0.000939	CcSEcCtD
L-DOPA—Hypersensitivity—Etoposide—urinary bladder cancer	0.000503	0.000938	CcSEcCtD
L-DOPA—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000501	0.000934	CcSEcCtD
L-DOPA—Headache—Gemcitabine—urinary bladder cancer	0.000501	0.000934	CcSEcCtD
L-DOPA—Flushing—Epirubicin—urinary bladder cancer	0.0005	0.000932	CcSEcCtD
L-DOPA—Vomiting—Fluorouracil—urinary bladder cancer	0.0005	0.000932	CcSEcCtD
L-DOPA—Rhinitis—Doxorubicin—urinary bladder cancer	0.000499	0.000932	CcSEcCtD
L-DOPA—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000498	0.000929	CcSEcCtD
L-DOPA—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000496	0.000925	CcSEcCtD
L-DOPA—Rash—Fluorouracil—urinary bladder cancer	0.000495	0.000924	CcSEcCtD
L-DOPA—Dermatitis—Fluorouracil—urinary bladder cancer	0.000495	0.000923	CcSEcCtD
L-DOPA—Headache—Fluorouracil—urinary bladder cancer	0.000492	0.000918	CcSEcCtD
L-DOPA—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000492	0.000918	CcSEcCtD
L-DOPA—Dysgeusia—Methotrexate—urinary bladder cancer	0.00049	0.000915	CcSEcCtD
L-DOPA—Asthenia—Etoposide—urinary bladder cancer	0.00049	0.000913	CcSEcCtD
L-DOPA—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000488	0.000911	CcSEcCtD
L-DOPA—Back pain—Methotrexate—urinary bladder cancer	0.000484	0.000904	CcSEcCtD
L-DOPA—Pruritus—Etoposide—urinary bladder cancer	0.000483	0.000901	CcSEcCtD
L-DOPA—Arrhythmia—Epirubicin—urinary bladder cancer	0.000481	0.000897	CcSEcCtD
L-DOPA—Alopecia—Epirubicin—urinary bladder cancer	0.000476	0.000888	CcSEcCtD
L-DOPA—Nausea—Gemcitabine—urinary bladder cancer	0.000475	0.000886	CcSEcCtD
L-DOPA—Vomiting—Cisplatin—urinary bladder cancer	0.000474	0.000884	CcSEcCtD
L-DOPA—Vision blurred—Methotrexate—urinary bladder cancer	0.000472	0.000881	CcSEcCtD
L-DOPA—Mental disorder—Epirubicin—urinary bladder cancer	0.000472	0.00088	CcSEcCtD
L-DOPA—Rash—Cisplatin—urinary bladder cancer	0.00047	0.000876	CcSEcCtD
L-DOPA—Dermatitis—Cisplatin—urinary bladder cancer	0.000469	0.000875	CcSEcCtD
L-DOPA—Diarrhoea—Etoposide—urinary bladder cancer	0.000467	0.000871	CcSEcCtD
L-DOPA—Nausea—Fluorouracil—urinary bladder cancer	0.000467	0.000871	CcSEcCtD
L-DOPA—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000465	0.000867	CcSEcCtD
L-DOPA—Anaemia—Methotrexate—urinary bladder cancer	0.000463	0.000864	CcSEcCtD
L-DOPA—Flushing—Doxorubicin—urinary bladder cancer	0.000462	0.000863	CcSEcCtD
L-DOPA—Flatulence—Epirubicin—urinary bladder cancer	0.000462	0.000862	CcSEcCtD
L-DOPA—Tension—Epirubicin—urinary bladder cancer	0.00046	0.000858	CcSEcCtD
L-DOPA—Dysgeusia—Epirubicin—urinary bladder cancer	0.000459	0.000856	CcSEcCtD
L-DOPA—Nervousness—Epirubicin—urinary bladder cancer	0.000455	0.000849	CcSEcCtD
L-DOPA—Back pain—Epirubicin—urinary bladder cancer	0.000453	0.000846	CcSEcCtD
L-DOPA—Malaise—Methotrexate—urinary bladder cancer	0.000452	0.000843	CcSEcCtD
L-DOPA—Dizziness—Etoposide—urinary bladder cancer	0.000451	0.000842	CcSEcCtD
L-DOPA—Muscle spasms—Epirubicin—urinary bladder cancer	0.000451	0.000841	CcSEcCtD
L-DOPA—Leukopenia—Methotrexate—urinary bladder cancer	0.000448	0.000836	CcSEcCtD
L-DOPA—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000445	0.00083	CcSEcCtD
L-DOPA—Nausea—Cisplatin—urinary bladder cancer	0.000442	0.000826	CcSEcCtD
L-DOPA—Vision blurred—Epirubicin—urinary bladder cancer	0.000442	0.000824	CcSEcCtD
L-DOPA—Alopecia—Doxorubicin—urinary bladder cancer	0.00044	0.000821	CcSEcCtD
L-DOPA—Cough—Methotrexate—urinary bladder cancer	0.000437	0.000815	CcSEcCtD
L-DOPA—Mental disorder—Doxorubicin—urinary bladder cancer	0.000436	0.000814	CcSEcCtD
L-DOPA—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000435	0.000811	CcSEcCtD
L-DOPA—Convulsion—Methotrexate—urinary bladder cancer	0.000434	0.00081	CcSEcCtD
L-DOPA—Vomiting—Etoposide—urinary bladder cancer	0.000434	0.00081	CcSEcCtD
L-DOPA—Anaemia—Epirubicin—urinary bladder cancer	0.000433	0.000808	CcSEcCtD
L-DOPA—Agitation—Epirubicin—urinary bladder cancer	0.000431	0.000804	CcSEcCtD
L-DOPA—Rash—Etoposide—urinary bladder cancer	0.00043	0.000803	CcSEcCtD
L-DOPA—Dermatitis—Etoposide—urinary bladder cancer	0.00043	0.000802	CcSEcCtD
L-DOPA—Headache—Etoposide—urinary bladder cancer	0.000427	0.000798	CcSEcCtD
L-DOPA—Flatulence—Doxorubicin—urinary bladder cancer	0.000427	0.000797	CcSEcCtD
L-DOPA—Chest pain—Methotrexate—urinary bladder cancer	0.000426	0.000796	CcSEcCtD
L-DOPA—Tension—Doxorubicin—urinary bladder cancer	0.000426	0.000794	CcSEcCtD
L-DOPA—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000425	0.000792	CcSEcCtD
L-DOPA—Malaise—Epirubicin—urinary bladder cancer	0.000423	0.000789	CcSEcCtD
L-DOPA—Discomfort—Methotrexate—urinary bladder cancer	0.000421	0.000786	CcSEcCtD
L-DOPA—Nervousness—Doxorubicin—urinary bladder cancer	0.000421	0.000786	CcSEcCtD
L-DOPA—Syncope—Epirubicin—urinary bladder cancer	0.00042	0.000784	CcSEcCtD
L-DOPA—Leukopenia—Epirubicin—urinary bladder cancer	0.00042	0.000783	CcSEcCtD
L-DOPA—Back pain—Doxorubicin—urinary bladder cancer	0.000419	0.000783	CcSEcCtD
L-DOPA—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000417	0.000778	CcSEcCtD
L-DOPA—Palpitations—Epirubicin—urinary bladder cancer	0.000414	0.000773	CcSEcCtD
L-DOPA—Confusional state—Methotrexate—urinary bladder cancer	0.000412	0.000769	CcSEcCtD
L-DOPA—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000412	0.000769	CcSEcCtD
L-DOPA—Cough—Epirubicin—urinary bladder cancer	0.000409	0.000763	CcSEcCtD
L-DOPA—Vision blurred—Doxorubicin—urinary bladder cancer	0.000409	0.000763	CcSEcCtD
L-DOPA—Convulsion—Epirubicin—urinary bladder cancer	0.000406	0.000758	CcSEcCtD
L-DOPA—Nausea—Etoposide—urinary bladder cancer	0.000405	0.000756	CcSEcCtD
L-DOPA—Hypertension—Epirubicin—urinary bladder cancer	0.000405	0.000755	CcSEcCtD
L-DOPA—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000402	0.000751	CcSEcCtD
L-DOPA—Anaemia—Doxorubicin—urinary bladder cancer	0.000401	0.000748	CcSEcCtD
L-DOPA—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.0004	0.000747	CcSEcCtD
L-DOPA—Chest pain—Epirubicin—urinary bladder cancer	0.000399	0.000744	CcSEcCtD
L-DOPA—Agitation—Doxorubicin—urinary bladder cancer	0.000399	0.000744	CcSEcCtD
L-DOPA—Anxiety—Epirubicin—urinary bladder cancer	0.000398	0.000742	CcSEcCtD
L-DOPA—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000395	0.000737	CcSEcCtD
L-DOPA—Discomfort—Epirubicin—urinary bladder cancer	0.000394	0.000736	CcSEcCtD
L-DOPA—Malaise—Doxorubicin—urinary bladder cancer	0.000391	0.00073	CcSEcCtD
L-DOPA—Dry mouth—Epirubicin—urinary bladder cancer	0.00039	0.000728	CcSEcCtD
L-DOPA—Anorexia—Methotrexate—urinary bladder cancer	0.00039	0.000727	CcSEcCtD
L-DOPA—Syncope—Doxorubicin—urinary bladder cancer	0.000389	0.000726	CcSEcCtD
L-DOPA—Leukopenia—Doxorubicin—urinary bladder cancer	0.000388	0.000724	CcSEcCtD
L-DOPA—Confusional state—Epirubicin—urinary bladder cancer	0.000386	0.00072	CcSEcCtD
L-DOPA—Palpitations—Doxorubicin—urinary bladder cancer	0.000383	0.000715	CcSEcCtD
L-DOPA—Oedema—Epirubicin—urinary bladder cancer	0.000383	0.000714	CcSEcCtD
L-DOPA—Hypotension—Methotrexate—urinary bladder cancer	0.000382	0.000713	CcSEcCtD
L-DOPA—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000381	0.000711	CcSEcCtD
L-DOPA—Cough—Doxorubicin—urinary bladder cancer	0.000378	0.000706	CcSEcCtD
L-DOPA—Shock—Epirubicin—urinary bladder cancer	0.000376	0.000702	CcSEcCtD
L-DOPA—Convulsion—Doxorubicin—urinary bladder cancer	0.000376	0.000701	CcSEcCtD
L-DOPA—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000375	0.000699	CcSEcCtD
L-DOPA—Hypertension—Doxorubicin—urinary bladder cancer	0.000374	0.000699	CcSEcCtD
L-DOPA—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.00037	0.00069	CcSEcCtD
L-DOPA—Insomnia—Methotrexate—urinary bladder cancer	0.00037	0.00069	CcSEcCtD
L-DOPA—Chest pain—Doxorubicin—urinary bladder cancer	0.000369	0.000689	CcSEcCtD
L-DOPA—Anxiety—Doxorubicin—urinary bladder cancer	0.000368	0.000686	CcSEcCtD
L-DOPA—Paraesthesia—Methotrexate—urinary bladder cancer	0.000367	0.000685	CcSEcCtD
L-DOPA—Discomfort—Doxorubicin—urinary bladder cancer	0.000365	0.000681	CcSEcCtD
L-DOPA—Anorexia—Epirubicin—urinary bladder cancer	0.000365	0.00068	CcSEcCtD
L-DOPA—Dyspnoea—Methotrexate—urinary bladder cancer	0.000364	0.00068	CcSEcCtD
L-DOPA—Somnolence—Methotrexate—urinary bladder cancer	0.000363	0.000678	CcSEcCtD
L-DOPA—Dry mouth—Doxorubicin—urinary bladder cancer	0.000361	0.000674	CcSEcCtD
L-DOPA—Dyspepsia—Methotrexate—urinary bladder cancer	0.00036	0.000671	CcSEcCtD
L-DOPA—Hypotension—Epirubicin—urinary bladder cancer	0.000357	0.000667	CcSEcCtD
L-DOPA—Confusional state—Doxorubicin—urinary bladder cancer	0.000357	0.000666	CcSEcCtD
L-DOPA—Decreased appetite—Methotrexate—urinary bladder cancer	0.000355	0.000663	CcSEcCtD
L-DOPA—Oedema—Doxorubicin—urinary bladder cancer	0.000354	0.00066	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000353	0.000658	CcSEcCtD
L-DOPA—Fatigue—Methotrexate—urinary bladder cancer	0.000352	0.000658	CcSEcCtD
L-DOPA—Pain—Methotrexate—urinary bladder cancer	0.00035	0.000652	CcSEcCtD
L-DOPA—Shock—Doxorubicin—urinary bladder cancer	0.000348	0.00065	CcSEcCtD
L-DOPA—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000347	0.000647	CcSEcCtD
L-DOPA—Insomnia—Epirubicin—urinary bladder cancer	0.000346	0.000646	CcSEcCtD
L-DOPA—Paraesthesia—Epirubicin—urinary bladder cancer	0.000343	0.000641	CcSEcCtD
L-DOPA—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000342	0.000638	CcSEcCtD
L-DOPA—Dyspnoea—Epirubicin—urinary bladder cancer	0.000341	0.000636	CcSEcCtD
L-DOPA—Somnolence—Epirubicin—urinary bladder cancer	0.00034	0.000634	CcSEcCtD
L-DOPA—Anorexia—Doxorubicin—urinary bladder cancer	0.000337	0.000629	CcSEcCtD
L-DOPA—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000337	0.000628	CcSEcCtD
L-DOPA—Dyspepsia—Epirubicin—urinary bladder cancer	0.000337	0.000628	CcSEcCtD
L-DOPA—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000334	0.000624	CcSEcCtD
L-DOPA—Decreased appetite—Epirubicin—urinary bladder cancer	0.000333	0.00062	CcSEcCtD
L-DOPA—Hypotension—Doxorubicin—urinary bladder cancer	0.000331	0.000617	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.00033	0.000616	CcSEcCtD
L-DOPA—Fatigue—Epirubicin—urinary bladder cancer	0.00033	0.000615	CcSEcCtD
L-DOPA—Pain—Epirubicin—urinary bladder cancer	0.000327	0.00061	CcSEcCtD
L-DOPA—Constipation—Epirubicin—urinary bladder cancer	0.000327	0.00061	CcSEcCtD
L-DOPA—Urticaria—Methotrexate—urinary bladder cancer	0.000325	0.000606	CcSEcCtD
L-DOPA—Abdominal pain—Methotrexate—urinary bladder cancer	0.000323	0.000603	CcSEcCtD
L-DOPA—Insomnia—Doxorubicin—urinary bladder cancer	0.00032	0.000597	CcSEcCtD
L-DOPA—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000318	0.000593	CcSEcCtD
L-DOPA—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000316	0.000589	CcSEcCtD
L-DOPA—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000315	0.000588	CcSEcCtD
L-DOPA—Somnolence—Doxorubicin—urinary bladder cancer	0.000315	0.000587	CcSEcCtD
L-DOPA—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000313	0.000584	CcSEcCtD
L-DOPA—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000312	0.000581	CcSEcCtD
L-DOPA—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000308	0.000574	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000306	0.00057	CcSEcCtD
L-DOPA—Fatigue—Doxorubicin—urinary bladder cancer	0.000305	0.000569	CcSEcCtD
L-DOPA—Urticaria—Epirubicin—urinary bladder cancer	0.000304	0.000567	CcSEcCtD
L-DOPA—Pain—Doxorubicin—urinary bladder cancer	0.000303	0.000565	CcSEcCtD
L-DOPA—Constipation—Doxorubicin—urinary bladder cancer	0.000303	0.000565	CcSEcCtD
L-DOPA—Abdominal pain—Epirubicin—urinary bladder cancer	0.000302	0.000564	CcSEcCtD
L-DOPA—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000301	0.000562	CcSEcCtD
L-DOPA—Asthenia—Methotrexate—urinary bladder cancer	0.000293	0.000547	CcSEcCtD
L-DOPA—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000292	0.000544	CcSEcCtD
L-DOPA—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000289	0.00054	CcSEcCtD
L-DOPA—Pruritus—Methotrexate—urinary bladder cancer	0.000289	0.00054	CcSEcCtD
L-DOPA—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000282	0.000526	CcSEcCtD
L-DOPA—Urticaria—Doxorubicin—urinary bladder cancer	0.000281	0.000525	CcSEcCtD
L-DOPA—Abdominal pain—Doxorubicin—urinary bladder cancer	0.00028	0.000522	CcSEcCtD
L-DOPA—Diarrhoea—Methotrexate—urinary bladder cancer	0.00028	0.000522	CcSEcCtD
L-DOPA—Asthenia—Epirubicin—urinary bladder cancer	0.000274	0.000512	CcSEcCtD
L-DOPA—Pruritus—Epirubicin—urinary bladder cancer	0.000271	0.000505	CcSEcCtD
L-DOPA—Dizziness—Methotrexate—urinary bladder cancer	0.00027	0.000504	CcSEcCtD
L-DOPA—Diarrhoea—Epirubicin—urinary bladder cancer	0.000262	0.000488	CcSEcCtD
L-DOPA—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000261	0.000487	CcSEcCtD
L-DOPA—Vomiting—Methotrexate—urinary bladder cancer	0.00026	0.000485	CcSEcCtD
L-DOPA—Rash—Methotrexate—urinary bladder cancer	0.000258	0.000481	CcSEcCtD
L-DOPA—Dermatitis—Methotrexate—urinary bladder cancer	0.000257	0.00048	CcSEcCtD
L-DOPA—Headache—Methotrexate—urinary bladder cancer	0.000256	0.000478	CcSEcCtD
L-DOPA—Asthenia—Doxorubicin—urinary bladder cancer	0.000254	0.000474	CcSEcCtD
L-DOPA—Dizziness—Epirubicin—urinary bladder cancer	0.000253	0.000472	CcSEcCtD
L-DOPA—Pruritus—Doxorubicin—urinary bladder cancer	0.00025	0.000467	CcSEcCtD
L-DOPA—Vomiting—Epirubicin—urinary bladder cancer	0.000243	0.000454	CcSEcCtD
L-DOPA—Nausea—Methotrexate—urinary bladder cancer	0.000243	0.000453	CcSEcCtD
L-DOPA—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000242	0.000452	CcSEcCtD
L-DOPA—Rash—Epirubicin—urinary bladder cancer	0.000241	0.00045	CcSEcCtD
L-DOPA—Dermatitis—Epirubicin—urinary bladder cancer	0.000241	0.00045	CcSEcCtD
L-DOPA—Headache—Epirubicin—urinary bladder cancer	0.00024	0.000447	CcSEcCtD
L-DOPA—Dizziness—Doxorubicin—urinary bladder cancer	0.000234	0.000437	CcSEcCtD
L-DOPA—Nausea—Epirubicin—urinary bladder cancer	0.000227	0.000424	CcSEcCtD
L-DOPA—Vomiting—Doxorubicin—urinary bladder cancer	0.000225	0.00042	CcSEcCtD
L-DOPA—Rash—Doxorubicin—urinary bladder cancer	0.000223	0.000416	CcSEcCtD
L-DOPA—Dermatitis—Doxorubicin—urinary bladder cancer	0.000223	0.000416	CcSEcCtD
L-DOPA—Headache—Doxorubicin—urinary bladder cancer	0.000222	0.000414	CcSEcCtD
L-DOPA—Nausea—Doxorubicin—urinary bladder cancer	0.00021	0.000392	CcSEcCtD
L-DOPA—PSIP1—Disease—SRC—urinary bladder cancer	0.000141	0.000895	CbGpPWpGaD
L-DOPA—CYP2D6—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000139	0.000887	CbGpPWpGaD
L-DOPA—SLC7A8—Hemostasis—TP53—urinary bladder cancer	0.000139	0.000887	CbGpPWpGaD
L-DOPA—DRD1—Circadian rythm related genes—PTEN—urinary bladder cancer	0.000139	0.000887	CbGpPWpGaD
L-DOPA—DRD3—Circadian rythm related genes—PTEN—urinary bladder cancer	0.000137	0.000875	CbGpPWpGaD
L-DOPA—DDC—Metabolism—NQO1—urinary bladder cancer	0.000137	0.000873	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—KRAS—urinary bladder cancer	0.000137	0.000871	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—HDAC4—urinary bladder cancer	0.000136	0.000867	CbGpPWpGaD
L-DOPA—DRD3—G alpha (i) signalling events—CXCL8—urinary bladder cancer	0.000135	0.000859	CbGpPWpGaD
L-DOPA—SLC7A8—Hemostasis—HRAS—urinary bladder cancer	0.000133	0.000849	CbGpPWpGaD
L-DOPA—DRD1—Circadian rythm related genes—EP300—urinary bladder cancer	0.000133	0.000846	CbGpPWpGaD
L-DOPA—DRD3—Circadian rythm related genes—EP300—urinary bladder cancer	0.000131	0.000834	CbGpPWpGaD
L-DOPA—PSIP1—Disease—MYC—urinary bladder cancer	0.000126	0.000802	CbGpPWpGaD
L-DOPA—DRD5—GPCR ligand binding—CXCL8—urinary bladder cancer	0.000125	0.000793	CbGpPWpGaD
L-DOPA—PSIP1—Disease—EGFR—urinary bladder cancer	0.000123	0.000784	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—HDAC4—urinary bladder cancer	0.000123	0.000781	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—TP53—urinary bladder cancer	0.000122	0.000774	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—HDAC4—urinary bladder cancer	0.000121	0.00077	CbGpPWpGaD
L-DOPA—DRD4—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	0.000121	0.000769	CbGpPWpGaD
L-DOPA—PSIP1—Disease—KRAS—urinary bladder cancer	0.000116	0.000741	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—HRAS—urinary bladder cancer	0.000116	0.00074	CbGpPWpGaD
L-DOPA—DDC—Metabolism—GSTP1—urinary bladder cancer	0.000114	0.000728	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—GLI1—urinary bladder cancer	0.000114	0.000727	CbGpPWpGaD
L-DOPA—SLC15A1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	0.000112	0.00071	CbGpPWpGaD
L-DOPA—DRD1—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	0.000109	0.000692	CbGpPWpGaD
L-DOPA—DRD3—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	0.000107	0.000683	CbGpPWpGaD
L-DOPA—DDC—Metabolism—TYMS—urinary bladder cancer	0.000106	0.000677	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—RBX1—urinary bladder cancer	0.000106	0.000675	CbGpPWpGaD
L-DOPA—DRD4—Circadian rythm related genes—TP53—urinary bladder cancer	0.000106	0.000672	CbGpPWpGaD
L-DOPA—DRD2—Circadian rythm related genes—PTEN—urinary bladder cancer	0.000105	0.00067	CbGpPWpGaD
L-DOPA—DDC—Metabolism—NCOR1—urinary bladder cancer	0.000105	0.000669	CbGpPWpGaD
L-DOPA—DDC—Metabolism—GSTM1—urinary bladder cancer	0.000105	0.000669	CbGpPWpGaD
L-DOPA—DRD2—G alpha (i) signalling events—CXCL8—urinary bladder cancer	0.000103	0.000657	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—GLI1—urinary bladder cancer	0.000103	0.000654	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—GLI1—urinary bladder cancer	0.000101	0.000645	CbGpPWpGaD
L-DOPA—DDC—Metabolism—GPX1—urinary bladder cancer	0.000101	0.000641	CbGpPWpGaD
L-DOPA—DRD2—Circadian rythm related genes—EP300—urinary bladder cancer	0.0001	0.000638	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—TSC1—urinary bladder cancer	9.97e-05	0.000634	CbGpPWpGaD
L-DOPA—PSIP1—Disease—HRAS—urinary bladder cancer	9.9e-05	0.00063	CbGpPWpGaD
L-DOPA—DDC—Metabolism—ERCC2—urinary bladder cancer	9.89e-05	0.000629	CbGpPWpGaD
L-DOPA—DRD1—Circadian rythm related genes—TP53—urinary bladder cancer	9.51e-05	0.000605	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—JAG1—urinary bladder cancer	9.49e-05	0.000604	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GSTZ1—urinary bladder cancer	9.42e-05	0.0006	CbGpPWpGaD
L-DOPA—DRD3—Circadian rythm related genes—TP53—urinary bladder cancer	9.38e-05	0.000597	CbGpPWpGaD
L-DOPA—DDC—Metabolism—MTHFR—urinary bladder cancer	9.29e-05	0.000591	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—HDAC4—urinary bladder cancer	9.26e-05	0.000589	CbGpPWpGaD
L-DOPA—DRD4—GPCR ligand binding—CXCL8—urinary bladder cancer	9.2e-05	0.000585	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GSTO2—urinary bladder cancer	8.93e-05	0.000569	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—NAT1—urinary bladder cancer	8.93e-05	0.000569	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—CXCL8—urinary bladder cancer	8.28e-05	0.000527	CbGpPWpGaD
L-DOPA—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	8.21e-05	0.000522	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—UGT2B7—urinary bladder cancer	8.17e-05	0.00052	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—CXCL8—urinary bladder cancer	8.17e-05	0.00052	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—RHOA—urinary bladder cancer	8.02e-05	0.00051	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—RBX1—urinary bladder cancer	7.82e-05	0.000498	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—GLI1—urinary bladder cancer	7.76e-05	0.000494	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—S100B—urinary bladder cancer	7.68e-05	0.000489	CbGpPWpGaD
L-DOPA—DDC—Metabolism—PPARG—urinary bladder cancer	7.54e-05	0.00048	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	7.36e-05	0.000468	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TSC1—urinary bladder cancer	7.36e-05	0.000468	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—RHOA—urinary bladder cancer	7.28e-05	0.000464	CbGpPWpGaD
L-DOPA—DDC—Metabolism—CREBBP—urinary bladder cancer	7.24e-05	0.000461	CbGpPWpGaD
L-DOPA—DRD2—Circadian rythm related genes—TP53—urinary bladder cancer	7.18e-05	0.000457	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—RBX1—urinary bladder cancer	7.04e-05	0.000448	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—CXCL8—urinary bladder cancer	7.04e-05	0.000448	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—JAG1—urinary bladder cancer	7e-05	0.000446	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—RBX1—urinary bladder cancer	6.95e-05	0.000442	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	6.95e-05	0.000442	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—NCOR1—urinary bladder cancer	6.91e-05	0.00044	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	6.77e-05	0.000431	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—IL2—urinary bladder cancer	6.73e-05	0.000428	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TSC1—urinary bladder cancer	6.62e-05	0.000421	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TSC1—urinary bladder cancer	6.53e-05	0.000416	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—CXCL8—urinary bladder cancer	6.39e-05	0.000407	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—JAG1—urinary bladder cancer	6.3e-05	0.000401	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—CXCL8—urinary bladder cancer	6.25e-05	0.000398	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—JAG1—urinary bladder cancer	6.22e-05	0.000396	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—IL2—urinary bladder cancer	6.11e-05	0.000389	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—TERT—urinary bladder cancer	6.09e-05	0.000388	CbGpPWpGaD
L-DOPA—DDC—Metabolism—PTGS2—urinary bladder cancer	5.93e-05	0.000377	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—RHOA—urinary bladder cancer	5.92e-05	0.000377	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—S100B—urinary bladder cancer	5.67e-05	0.000361	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—FGFR3—urinary bladder cancer	5.59e-05	0.000356	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—ESR1—urinary bladder cancer	5.43e-05	0.000345	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—TYMP—urinary bladder cancer	5.41e-05	0.000345	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—RHOA—urinary bladder cancer	5.38e-05	0.000342	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—RHOA—urinary bladder cancer	5.33e-05	0.000339	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—RBX1—urinary bladder cancer	5.32e-05	0.000338	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—RHOA—urinary bladder cancer	5.26e-05	0.000335	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—CXCL8—urinary bladder cancer	5.2e-05	0.000331	CbGpPWpGaD
L-DOPA—DDC—Metabolism—PTEN—urinary bladder cancer	5.17e-05	0.000329	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—S100B—urinary bladder cancer	5.11e-05	0.000325	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—NCOR1—urinary bladder cancer	5.1e-05	0.000325	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—S100B—urinary bladder cancer	5.04e-05	0.000321	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TSC1—urinary bladder cancer	5e-05	0.000318	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—IL2—urinary bladder cancer	4.97e-05	0.000316	CbGpPWpGaD
L-DOPA—DDC—Metabolism—EP300—urinary bladder cancer	4.93e-05	0.000314	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—NAT2—urinary bladder cancer	4.9e-05	0.000312	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—RHOA—urinary bladder cancer	4.84e-05	0.000308	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—RHOA—urinary bladder cancer	4.78e-05	0.000304	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—JAG1—urinary bladder cancer	4.76e-05	0.000303	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CREBBP—urinary bladder cancer	4.76e-05	0.000303	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—CXCL8—urinary bladder cancer	4.72e-05	0.0003	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—IGF1—urinary bladder cancer	4.7e-05	0.000299	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—CXCL8—urinary bladder cancer	4.68e-05	0.000298	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—EGFR—urinary bladder cancer	4.67e-05	0.000297	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—CXCL8—urinary bladder cancer	4.62e-05	0.000294	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—NCOR1—urinary bladder cancer	4.59e-05	0.000292	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—NCOR1—urinary bladder cancer	4.53e-05	0.000288	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—IL2—urinary bladder cancer	4.51e-05	0.000287	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TERT—urinary bladder cancer	4.49e-05	0.000286	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—IL2—urinary bladder cancer	4.47e-05	0.000285	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—KRAS—urinary bladder cancer	4.42e-05	0.000281	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—IL2—urinary bladder cancer	4.41e-05	0.000281	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—RHOA—urinary bladder cancer	4.3e-05	0.000274	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—CXCL8—urinary bladder cancer	4.25e-05	0.00027	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—RRM2—urinary bladder cancer	4.23e-05	0.000269	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—CXCL8—urinary bladder cancer	4.19e-05	0.000267	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—FGFR3—urinary bladder cancer	4.12e-05	0.000262	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—IL2—urinary bladder cancer	4.06e-05	0.000258	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TERT—urinary bladder cancer	4.05e-05	0.000257	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—RHOA—urinary bladder cancer	4.02e-05	0.000256	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—IL2—urinary bladder cancer	4.01e-05	0.000255	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—ESR1—urinary bladder cancer	4.01e-05	0.000255	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TERT—urinary bladder cancer	3.99e-05	0.000254	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—ERBB2—urinary bladder cancer	3.98e-05	0.000254	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	3.91e-05	0.000249	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ENO2—urinary bladder cancer	3.91e-05	0.000249	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—S100B—urinary bladder cancer	3.85e-05	0.000245	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	3.8e-05	0.000242	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CXCL8—urinary bladder cancer	3.78e-05	0.00024	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—HRAS—urinary bladder cancer	3.75e-05	0.000239	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—FGFR3—urinary bladder cancer	3.71e-05	0.000236	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—FGFR3—urinary bladder cancer	3.66e-05	0.000233	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—RHOA—urinary bladder cancer	3.65e-05	0.000233	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—IL2—urinary bladder cancer	3.61e-05	0.00023	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—ESR1—urinary bladder cancer	3.61e-05	0.000229	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—ESR1—urinary bladder cancer	3.56e-05	0.000226	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—CXCL8—urinary bladder cancer	3.53e-05	0.000225	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CCND1—urinary bladder cancer	3.52e-05	0.000224	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CREBBP—urinary bladder cancer	3.51e-05	0.000223	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IGF1—urinary bladder cancer	3.47e-05	0.000221	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NCOR1—urinary bladder cancer	3.47e-05	0.000221	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—EGFR—urinary bladder cancer	3.45e-05	0.00022	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MMP9—urinary bladder cancer	3.42e-05	0.000217	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CDKN1A—urinary bladder cancer	3.4e-05	0.000217	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PTEN—urinary bladder cancer	3.4e-05	0.000216	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—IL2—urinary bladder cancer	3.38e-05	0.000215	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—KRAS—urinary bladder cancer	3.26e-05	0.000207	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—EP300—urinary bladder cancer	3.24e-05	0.000206	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CXCL8—urinary bladder cancer	3.21e-05	0.000204	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—RHOA—urinary bladder cancer	3.18e-05	0.000202	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CREBBP—urinary bladder cancer	3.16e-05	0.000201	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—NQO1—urinary bladder cancer	3.15e-05	0.000201	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—SRC—urinary bladder cancer	3.15e-05	0.0002	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IGF1—urinary bladder cancer	3.12e-05	0.000199	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CREBBP—urinary bladder cancer	3.12e-05	0.000198	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—EGFR—urinary bladder cancer	3.11e-05	0.000198	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IGF1—urinary bladder cancer	3.08e-05	0.000196	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—IL2—urinary bladder cancer	3.07e-05	0.000195	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—EGFR—urinary bladder cancer	3.06e-05	0.000195	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TERT—urinary bladder cancer	3.05e-05	0.000194	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—ERBB2—urinary bladder cancer	2.94e-05	0.000187	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—KRAS—urinary bladder cancer	2.93e-05	0.000187	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—KRAS—urinary bladder cancer	2.89e-05	0.000184	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—RHOA—urinary bladder cancer	2.86e-05	0.000182	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MYC—urinary bladder cancer	2.82e-05	0.00018	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—RHOA—urinary bladder cancer	2.82e-05	0.00018	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—FGFR3—urinary bladder cancer	2.8e-05	0.000178	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CXCL8—urinary bladder cancer	2.79e-05	0.000177	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—HRAS—urinary bladder cancer	2.77e-05	0.000176	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—EGFR—urinary bladder cancer	2.76e-05	0.000176	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ESR1—urinary bladder cancer	2.72e-05	0.000173	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IL2—urinary bladder cancer	2.66e-05	0.00017	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—ERBB2—urinary bladder cancer	2.65e-05	0.000168	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	2.63e-05	0.000167	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—ERBB2—urinary bladder cancer	2.61e-05	0.000166	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—KRAS—urinary bladder cancer	2.61e-05	0.000166	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CCND1—urinary bladder cancer	2.6e-05	0.000165	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MMP9—urinary bladder cancer	2.52e-05	0.00016	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CDKN1A—urinary bladder cancer	2.51e-05	0.00016	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CXCL8—urinary bladder cancer	2.51e-05	0.00016	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PTEN—urinary bladder cancer	2.51e-05	0.00016	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—HRAS—urinary bladder cancer	2.49e-05	0.000159	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CXCL8—urinary bladder cancer	2.48e-05	0.000158	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—HRAS—urinary bladder cancer	2.46e-05	0.000157	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—TYMS—urinary bladder cancer	2.45e-05	0.000156	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	2.42e-05	0.000154	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	2.42e-05	0.000154	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IL2—urinary bladder cancer	2.4e-05	0.000153	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—EP300—urinary bladder cancer	2.39e-05	0.000152	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CREBBP—urinary bladder cancer	2.39e-05	0.000152	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IL2—urinary bladder cancer	2.37e-05	0.000151	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IGF1—urinary bladder cancer	2.36e-05	0.00015	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—EGFR—urinary bladder cancer	2.34e-05	0.000149	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CCND1—urinary bladder cancer	2.34e-05	0.000149	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—SRC—urinary bladder cancer	2.32e-05	0.000148	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—TP53—urinary bladder cancer	2.32e-05	0.000148	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GPX1—urinary bladder cancer	2.32e-05	0.000147	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CCND1—urinary bladder cancer	2.31e-05	0.000147	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	2.27e-05	0.000145	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MMP9—urinary bladder cancer	2.27e-05	0.000144	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CDKN1A—urinary bladder cancer	2.26e-05	0.000144	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PTEN—urinary bladder cancer	2.26e-05	0.000144	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MMP9—urinary bladder cancer	2.24e-05	0.000143	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CDKN1A—urinary bladder cancer	2.23e-05	0.000142	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PTEN—urinary bladder cancer	2.23e-05	0.000142	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—HRAS—urinary bladder cancer	2.22e-05	0.000141	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—KRAS—urinary bladder cancer	2.21e-05	0.000141	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—RHOA—urinary bladder cancer	2.16e-05	0.000137	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—EP300—urinary bladder cancer	2.15e-05	0.000137	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	2.14e-05	0.000136	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—EP300—urinary bladder cancer	2.12e-05	0.000135	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—SRC—urinary bladder cancer	2.09e-05	0.000133	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MYC—urinary bladder cancer	2.08e-05	0.000133	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—SRC—urinary bladder cancer	2.07e-05	0.000131	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—EGFR—urinary bladder cancer	2.04e-05	0.00013	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ERBB2—urinary bladder cancer	2e-05	0.000127	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—KRAS—urinary bladder cancer	1.93e-05	0.000123	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CXCL8—urinary bladder cancer	1.89e-05	0.000121	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—HRAS—urinary bladder cancer	1.88e-05	0.00012	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MYC—urinary bladder cancer	1.88e-05	0.000119	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MYC—urinary bladder cancer	1.85e-05	0.000118	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—EGFR—urinary bladder cancer	1.83e-05	0.000117	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IL2—urinary bladder cancer	1.81e-05	0.000115	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—EGFR—urinary bladder cancer	1.81e-05	0.000115	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CCND1—urinary bladder cancer	1.77e-05	0.000112	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—KRAS—urinary bladder cancer	1.73e-05	0.00011	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PPARG—urinary bladder cancer	1.73e-05	0.00011	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MMP9—urinary bladder cancer	1.71e-05	0.000109	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TP53—urinary bladder cancer	1.71e-05	0.000109	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—KRAS—urinary bladder cancer	1.71e-05	0.000109	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CDKN1A—urinary bladder cancer	1.71e-05	0.000109	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PTEN—urinary bladder cancer	1.7e-05	0.000108	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	1.66e-05	0.000106	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—HRAS—urinary bladder cancer	1.64e-05	0.000104	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—EP300—urinary bladder cancer	1.62e-05	0.000103	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—SRC—urinary bladder cancer	1.58e-05	0.000101	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TP53—urinary bladder cancer	1.54e-05	9.8e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TP53—urinary bladder cancer	1.52e-05	9.67e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—HRAS—urinary bladder cancer	1.47e-05	9.38e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—HRAS—urinary bladder cancer	1.45e-05	9.25e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MYC—urinary bladder cancer	1.42e-05	9.01e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—EGFR—urinary bladder cancer	1.39e-05	8.81e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	1.36e-05	8.67e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—KRAS—urinary bladder cancer	1.31e-05	8.33e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PTEN—urinary bladder cancer	1.19e-05	7.57e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TP53—urinary bladder cancer	1.16e-05	7.4e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—EP300—urinary bladder cancer	1.13e-05	7.21e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—HRAS—urinary bladder cancer	1.11e-05	7.08e-05	CbGpPWpGaD
